PT Phapros, Tbk

Jakarta Stock Exchange PEHA.JK

PT Phapros, Tbk Return on Capital Employed (ROCE) for the year ending December 31, 2023: 6.94%

PT Phapros, Tbk Return on Capital Employed (ROCE) is 6.94% for the year ending December 31, 2023, a -25.25% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

PT Phapros, Tbk Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 9.28%, a 10.81% change year over year.
PT Phapros, Tbk Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 8.37%, a -53.95% change year over year.
PT Phapros, Tbk Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 18.18%, a -13.77% change year over year.
PT Phapros, Tbk Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 21.08%, a -14.97% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Jakarta Stock Exchange: PEHA.JK

PT Phapros, Tbk

CEO	Ms. Ida Rahmi Kurniasih
IPO Date	Dec. 26, 2018
Location	Indonesia
Headquarters	Rajawali Tower 17th Floor
Employees	1,384
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia. The company operates through Over the Counter (OTC), Ethical, Generic Drugs Bearing, and Toll Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others. The company also provides generic drug products for government institutions and hospitals, as well as produces drugs for other pharmaceutical industries; and offers medical devices. PT Phapros, Tbk also exports its products internationally. The company was founded in 1954 and is headquartered in Jakarta, Indonesia. PT Phapros, Tbk operates as a subsidiary of PT Kimia Farma (Persero) Tbk.

Key trends

Past 5 years